INTRODUCTION
============

In Japan, incidence rates of lung cancer have levelled off for males and are increasing for females. Mortality rates of lung cancer show a decreasing trend for males and have levelled off for females.^[@r01]^ It was previously reported that incidence rates of lung cancer in Osaka had levelled off for males but increased for females, and that mortality rates showed a slightly decreasing trend for males and females in an analysis using the joinpoint regression model.^[@r02]^

Smoking is a major risk factor for lung cancer. The population attributable fraction of active smoking to lung cancer mortality is about 70% for males and 20--40% for females.^[@r03],[@r04]^ However, trends for lung cancer incidence vary by histological type. Previously, it was reported that incidence rates of adenocarcinoma (ADC) increased and incidence rates of squamous cell carcinoma (SQC) and small cell carcinoma (SMC) decreased for both genders in Osaka, Japan.^[@r05],[@r06]^ Incidence rates of SQC and SMC increased among younger groups in their 40s and 50s and older groups aged more than 70 years in the 1990s, but decreased or levelled off among intermediate groups in their 60s. Incidence rates of ADC were reported to increase among most age groups.^[@r07]^

In the present study, we updated the trends in lung cancer incidence and mortality rates for all histological types and estimated incidence rates by histological type and age group in Osaka, Japan.

METHODS
=======

Lung cancer incidence data for 1975--2008 were obtained from the Osaka Cancer Registry (OCR). Lung cancer mortality data in Osaka from 1975--2012 were obtained from vital statistics. Population data by sex and 5-year age group in Osaka were obtained from the National Census. This study was approved by the data usage committee of the OCR at the Osaka Medical Center for Cancer and Cardiovascular Diseases (Osaka, Japan) in August 2014 (approval ID: No. 14-0008).

When analyzing incidence rates by histological type, we followed the histological classification for lung tumors published by the World Health Organization.^[@r08]^ Histological types were categorized as follows: SQC (International Classification of Diseases for Oncology Third Edition, Morphology \[ICD-O-3M\]: 8050--8078, and 8083--8084), ADC (ICD-O-3M: 8140, 8211, 8230--8231, 8250--8260, 8323, 8480--8490, 8550--8551, 8570--8574, and 8576), SMC (ICD-O-3M: 8041--8045, and 8246), unspecified malignant neoplasm (ICD-O-3M: 8000--8005), and other specified malignant neoplasm. The data from the OCR included cases without specific histological diagnosis and stage. To include the missing data for histological type and stage in our analysis, we applied multiple imputation (MI).^[@r09],[@r10]^ For the imputation, we used a multinomial logistic regression model that included another incomplete variable and the complete variables: sex, age at diagnosis, period of diagnosis, and vital status. For the MI method, we used the *ice* command in Stata version 12 (STATA Corporation, College Station, TX, USA) and obtained 10 complete data sets.^[@r11],[@r12]^ When analyzing incidence rates by age group, age at diagnosis was classified into three categories: 35--64 years old, 65--74 years old, and over 75 years old, which were age-standardized within those age ranges.

First, we calculated annual age-standardized incidence and mortality rates (ASR) of lung cancer for all histological types and truncated age-standardized incidence rates by age group. We used the Japanese model population for 1985 to standardize age distribution. When analyzing by histological type, we used the 10 complete data sets obtained from the MI method. Second, we applied the joinpoint regression model^[@r13],[@r14]^ to identify the years when the statistically significant changes in incidence or mortality trends occurred using the Joinpoint Regression Program 4.1.0 (National Cancer Institute Surveillance Research Program Statistical Methodology and Applications Branch, Bethesda, MD, USA).^[@r15]^ In the joinpoint analysis, we used the logarithmic ASR as the dependent variable and the year of diagnosis or death as the independent variable. We found the best joinpoints (years when trends changed) using the permutation test method. Annual percentage change (APC) of each line segment between joinpoints was estimated in the model, and the APC was tested to see whether it was significantly different from 0 (*P* \< 0.05). We set three joinpoints as a maximum number in each analysis. We used Stata version 12 for all analyses except the joinpoint regression analysis.^[@r11]^

RESULTS
=======

The characteristics of patients before and after multiple imputation are shown in Table [1](#tbl01){ref-type="table"}. The proportion of patients with ADC increased while that with SQC and SMC decreased from the 1990s, and ADC has become a major histological type for both genders. The proportion of patients in the older age group (\>75 years old) increased, while that of the younger age group (\<65 years old) decreased.

###### Characteristics of patients stratified by sex, diagnostic period, histological type, stage, and age group

                                              Year                                                                                                       
  ------------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ -------- ------
  Males                                                                                                                                                  
   Histological type (before imputation^a^)                                                                                                              
    Squamous cell carcinoma                   1038   18.6   1953   25.3   2664   25.8   2997   23.9   3936   25.1   4487   23.8   3853   22.0   20 928   23.7
    Adenocarcinoma                            913    16.3   1702   22.0   2556   24.8   3023   24.1   4645   29.6   5909   31.3   5859   33.5   24 607   27.9
    Small cell carcinoma                      321    5.7    754    9.8    1124   10.9   1395   11.1   1794   11.4   2134   11.3   1843   10.5   9365     10.6
    Others                                    221    4.0    480    6.2    700    6.8    669    5.3    780    5.0    1028   5.4    1333   7.6    5211     5.9
    Missing                                   3095   55.4   2841   36.8   3278   31.8   4440   35.5   4530   28.9   5325   28.2   4614   26.4   28 123   31.9
   Histological type (after imputation)                                                                                                                  
    Squamous cell carcinoma                   2370   42.4   3200   41.4   3956   38.3   4740   37.9   5572   35.5   6423   34.0   5308   30.3   31 568   35.8
    Adenocarcinoma                            1954   35.0   2628   34.0   3706   35.9   4555   36.4   6432   41.0   7986   42.3   7801   44.6   35 062   39.7
    Small cell carcinoma                      772    13.8   1168   15.1   168    16.3   2177   17.4   2584   16.5   3072   16.3   2613   14.9   14 069   15.9
    Others                                    492    8.8    735    9.5    977    9.5    1052   8.4    1098   7.0    1403   7.4    1780   10.2   7536     8.5
   Stage^b^ (before imputation)                                                                                                                          
    Localised                                 657    11.8   867    11.2   1158   11.2   1340   10.7   2022   12.9   2694   14.3   2797   16.0   11 535   13.1
    Regional                                  1525   27.3   2078   26.9   2900   28.1   3377   27.0   4209   26.8   4694   24.9   4077   23.3   22 860   25.9
    Distant                                   1121   20.1   1949   25.2   2757   26.7   2997   23.9   3840   24.5   4929   26.1   5334   30.5   22 927   26.0
    Missing                                   2285   40.9   2836   36.7   3507   34.0   4810   38.4   5614   35.8   6566   34.8   5294   30.3   30 912   35.0
   Stage (after imputation)                                                                                                                              
    Localised                                 1084   19.4   1404   18.2   1756   17.0   2142   17.1   2943   18.8   3814   20.2   3497   20.0   16 640   18.9
    Regional                                  2492   44.6   3290   42.6   4351   42.2   5380   43.0   6521   41.6   7414   39.3   6048   34.6   35 496   40.2
    Distant                                   2012   36.0   3037   39.3   4214   40.8   5003   40.0   6220   39.7   7655   40.5   7957   45.5   36 098   40.9
   Age group, years                                                                                                                                      
    15--34                                    42     0.8    45     0.6    34     0.3    43     0.3    43     0.3    57     0.3    32     0.2    296      0.3
    35--64                                    2077   37.2   2561   33.1   3547   34.4   4105   32.8   4684   29.9   5129   27.2   4200   24.0   26 303   29.8
    65--74                                    2276   40.7   3040   39.3   3466   33.6   4141   33.1   5731   36.5   6853   36.3   6093   34.8   31 600   35.8
    ≥75                                       1193   21.4   2084   27.0   3275   31.7   4235   33.8   5227   33.3   6844   36.2   7177   41.0   30 035   34.0
  Females                                                                                                                                                
   Histological type (before imputation)                                                                                                                 
    Squamous cell carcinoma                   170    8.1    285    9.7    472    11.6   504    9.9    677    10.4   759    9.4    641    8.5    3508     9.7
    Adenocarcinoma                            507    24.1   970    33.1   1443   35.5   1862   36.5   2850   43.8   3690   45.8   3722   49.5   15 044   41.5
    Small cell carcinoma                      68     3.2    215    7.3    310    7.6    390    7.6    510    7.8    537    6.7    462    6.1    2492     6.9
    Others                                    59     2.8    119    4.1    187    4.6    205    4.0    221    3.4    287    3.6    355    4.7    1433     4.0
    Missing                                   1296   61.7   1341   45.8   1659   40.8   2145   42.0   2246   34.5   2777   34.5   2346   31.2   13 810   38.1
   Histological type (after imputation)                                                                                                                  
    Squamous cell carcinoma                   454    21.6   584    20.0   801    19.7   936    18.3   1058   16.3   1241   15.4   981    13.0   6056     16.7
    Adenocarcinoma                            1269   60.4   1748   59.7   2420   59.5   3128   61.3   4295   66.0   5472   68.0   5275   70.1   23 607   65.1
    Small cell carcinoma                      224    10.7   388    13.2   550    13.5   697    13.6   811    12.5   910    11.3   747    9.9    4326     11.9
    Others                                    153    7.3    210    7.2    299    7.4    345    6.8    341    5.2    427    5.3    523    7.0    2299     6.3
   Stage (before imputation)                                                                                                                             
    Localised                                 206    9.8    276    9.4    395    9.7    545    10.7   954    14.7   1549   19.2   1585   21.1   5510     15.2
    Regional                                  540    25.7   662    22.6   951    23.4   1107   21.7   1504   23.1   1493   18.6   1338   17.8   7595     20.9
    Distant                                   426    20.3   781    26.7   1099   27.0   1251   24.5   1527   23.5   2036   25.3   2067   27.5   9187     25.3
    Missing                                   928    44.2   1211   41.3   1626   39.9   2203   43.2   2519   38.7   2972   36.9   2536   33.7   13 995   38.6
   Stage (after imputation)                                                                                                                              
    Localised                                 367    17.5   489    16.7   659    16.2   891    17.5   1354   20.8   2058   25.6   1914   25.4   7731     21.3
    Regional                                  923    44.0   1169   39.9   1628   40.0   2013   39.4   2521   38.8   2716   33.7   2269   30.2   13 239   36.5
    Distant                                   810    38.6   1272   43.4   1784   43.8   2202   43.1   2629   40.4   3276   40.7   3343   44.4   15 317   42.2
   Age group, years                                                                                                                                      
    15--34                                    32     1.5    24     0.8    25     0.6    27     0.5    27     0.4    33     0.4    25     0.3    193      0.5
    35--64                                    798    38.0   960    32.8   1192   29.3   1460   28.6   1805   27.8   2128   26.4   1807   24.0   10 150   28.0
    65--74                                    786    37.4   1043   35.6   1343   33.0   1511   29.6   1830   28.1   2245   27.9   2166   28.8   10 924   30.1
    ≥75                                       484    23.1   903    30.8   1511   37.1   2108   41.3   2842   43.7   3644   45.3   3528   46.9   15 020   41.4

^a^The number and proportion by stage and histological type are calculated before and after multiple imputation.

^b^Stage at diagnosis is classified into three groups: localised (cancer is confined to the organ from which is originated, regional (cancer metastasizes into regional lymph nodes and/or invades adjacent organs), distant (cancer metastasizes to distant organs and/or lymph nodes).

Trends in lung cancer incidence and mortality rates for all histological types are shown in Figure [1](#fig01){ref-type="fig"} and Table [2](#tbl02){ref-type="table"}. Incidence rates steeply increased by 3.5% (95% CI, 2.9%--4.1%) per year for males and 3.7% (95% CI, 2.6%--4.8%) per year for females until 1985--86. Trends in incidence rates then slightly increased, as APC was 0.3% (95% CI, 0.1%--0.4%) for males and 1.1% (95% CI, 0.9%--1.3%) for females. Mortality rates levelled off from 1988 and slightly decreased from 1997 for males (APC −0.9%; 95% CI, −1.2% to −0.7%). For females, mortality rates decreased from 1989 (APC −0.5%; 95% CI, −0.8% to −0.3%).

![Trends in age-standardized incidence and mortality rates for lung cancer in Osaka, Japan from 1975 to 2008.](je-26-579-g001){#fig01}

###### Trends in age-standardized incidence and mortality rates of lung cancer with joinpoint analysis in Osaka, Japan

              Trend 1      Trend 2   Trend 3                                                                   
  ----------- ------------ --------- ------------ ------------ --------- -------------- ------------ --------- --------------
  Incidence                                                                                                    
   Males      1975--1986   3.5^a^    (2.9, 4.1)   1986--2008   0.3^a^    (0.1, 0.4)                             
   Females    1975--1985   3.7^a^    (2.6, 4.8)   1985--2008   1.1^a^    (0.9, 1.3)                             
                                                                                                               
  Mortality                                                                                                    
   Males      1975--1988   3.0^a^    (2.5, 3.6)   1988--1997   0.2       (−0.5, 1.0)    1997--2012   −0.9^a^   (−1.2, −0.7)
   Females    1975--1989   3.5^a^    (2.6, 4.4)   1989--2012   −0.5^a^   (−0.8, −0.3)                           

APC, annual percentage change; CI, confidence interval.

^a^APC is statistically significantly different from zero (*P* \< 0.05).

Figure [2](#fig02){ref-type="fig"} and Table [3](#tbl03){ref-type="table"} show trends in lung cancer incidence rates by histological type. The peak incidence of SQC was observed in 1996 for males and in 1986 for females. Incidence rates of SQC decreased for males (APC −1.9%; 95% CI, −2.4% to −1.5%) and females (APC −1.3%; 95% CI, −1.7% to −0.9%). ADC increased by 1.1% (95% CI, 0.8%--1.5%) for males and by 2.3% (95% CI, 2.1%--2.5%) for females. The rates of SMC decreased from 1992 for males (APC −0.9%; 95% CI, −1.3% to −0.4%) and from 1988 for females (APC −1.3%; 95% CI, −1.9% to −0.7%). The incidence rate of ADC overtook that of SQC for males in the 1990s.

![Trends in age-standardized incidence rates of lung cancer by histological type in Osaka, Japan 1975 to 2008. ADC, adenocarcinoma; SMC, small cell carcinoma; SQC, squamous cell carcinoma.](je-26-579-g002){#fig02}

###### Trends in age-standardized incidence rates of lung cancer by histological type with joinpoint analysis in Osaka, Japan

  Histological type          Trend 1      Trend 2   Trend 3      Trend 4                                                                                           
  -------------------------- ------------ --------- ------------ ------------ --------- -------------- ------------ --------- -------------- ------------ -------- ------------
  Males                                                                                                                                                            
   Squamous cell carcinoma   1975--1985   2.7^a^    (1.7, 3.7)   1985--1996   0         (−0.8, 0.7)    1996--2008   −1.9^a^   (−2.4, −1.5)                          
   Adenocarcinoma            1975--1987   3.4^a^    (2.7, 4.1)   1987--1991   −0.4      (−4.8, 4.3)    1991--1996   4.0^a^    (1.4, 6.6)     1996--2008   1.1^a^   (0.8, 1.5)
   Small cell carcinoma      1975--1985   6.0^a^    (4.5, 7.6)   1985--1992   1.7       (−0.6, 4.1)    1992--2008   −0.9^a^   (−1.3, −0.4)                          
  Females                                                                                                                                                          
   Squamous cell carcinoma   1975--1986   3.1^a^    (1.4, 4.8)   1986--2008   −1.3^a^   (−1.7, −0.9)                                                                
   Adenocarcinoma            1975--2008   2.3^a^    (2.1, 2.5)                                                                                                      
   Small cell carcinoma      1975--1988   5.8^a^    (3.9, 7.8)   1988--2008   −1.3^a^   (−1.9, −0.7)                                                                

APC, annual percentage change; CI, confidence interval.

^a^APC is statistically significantly different from zero (*P* \< 0.05).

We also analyzed truncated age-standardized incidence rates by histological type and age group ([eFigure 1](#sm04){ref-type="supplementary-material"}, [eFigure 2](#sm05){ref-type="supplementary-material"}, [eFigure 3](#sm06){ref-type="supplementary-material"}, [eTable 1](#sm01){ref-type="supplementary-material"}, [eTable 2](#sm02){ref-type="supplementary-material"}, and [eTable 3](#sm03){ref-type="supplementary-material"}). [eFigure 1](#sm04){ref-type="supplementary-material"} and [eTable 1](#sm01){ref-type="supplementary-material"} show trends in truncated (35--64 years, 65--74 years, and ≥75 years) age-standardized incidence rate of SQC by age group. For the age group 35--64 years, the rate continued to decrease in males (APC −1.0%; 95% CI, −1.3% to −0.8%), while it remained stable in females. For the age groups 65--74 years and ≥75 years, the rate significantly decreased for both genders. [eFigure 2](#sm05){ref-type="supplementary-material"} and [eTable 2](#sm02){ref-type="supplementary-material"} show trends in ADC. Among all age groups in males and females, except the age group 65--74 years in males, the rate significantly increased. The rate among the age group 65--74 years in males levelled off in 1997--2008. [eFigure 3](#sm06){ref-type="supplementary-material"} and [eTable 3](#sm06){ref-type="supplementary-material"} show trends in SMC by age group. Among the male age groups 35--64 years and 65--74 years and female age groups 65--74 years and ≥75 years, the rate decreased recently. However, the rate levelled off among the male age group ≥75 years and female age group 35--64 years.

DISCUSSION
==========

Although trends in incidence and mortality rates steeply increased in parallel from 1975 to the 1980s, the incidence rate increased slightly and the mortality rate decreased slightly from 1980s onwards. The latest APC of incidence rates was higher for females than males (0.3% vs 1.1%). Histologically specific analysis showed a continuous increase in ADC and a decrease in SQC and SMC since around 1990.

Trends in the incidence and mortality rates for all histological types
----------------------------------------------------------------------

Changes in incidence and mortality rates in the 1980s may be due to the decline in smoking prevalence because smoking habits are closely related to the incidence and mortality of lung cancer and other comorbidities.^[@r03]^ The increasingly widespread use of computed tomography (CT) might in part have contributed to the slight increase in incidence and the slight decrease in mortality observed from the late 1980s. It has been reported that the detection rate of CT scanning is higher than that of x-ray or sputum cytology, and cases detected by CT are likely to be early stage and peripherally located ADC.^[@r16],[@r17]^ These cancers can be easily treated by surgery, which might have led to the decrease in mortality. However, low-dose CT screening, which was introduced in the 1990s in Japan, is experimentally conducted only in some specific areas, while CT scanning has been widely used in various clinical scenarios, such as chest pain, hemosputum, fever, faint abnormal shadow in chest x-ray, and screening for metastasis from other organ cancers. Therefore, it is difficult to evaluate the effects of CT scanning on the trends in lung cancer. The introduction and diffusion of tyrosine kinase inhibitors, such as gefitinib, which is an effective drug for advanced ADC with epidermal growth factor receptor (EGFR) mutations,^[@r18]^ might also have partially contributed to the decrease in mortality.

To better understand these incidence and mortality trends, we also confirmed trends in the proportion of early stage cancer diagnosed as a localized cancer. In population-based cancer registries in Japan, stage at diagnosis is classified into three categories: localized, regional metastases (regional lymph nodes and adjacent organs), and distant metastasis. The proportion of patients with localized cancer slightly increased from the 1990s, especially in females. Moreover, the proportion of patients with ADC was higher in females than males (Table [1](#tbl01){ref-type="table"}). The gender differences in the distribution of histological type and stage of lung cancer might reflect different trends in incidence and mortality between genders.

Cigarette smoking and trends in the incidence rates of SQC and SMC
------------------------------------------------------------------

It is known that the incidence of SQC and SMC is more closely related to smoking behaviors than that of ADC.^[@r19],[@r20]^ Japanese smoking prevalence decreased from the 1960s for both genders (from 82.3% in 1965 to 38.9% in 2009 for males, and from 15.7% in 1965 to 11.9% in 2009 for females) ([eFigure 4](#sm07){ref-type="supplementary-material"}).^[@r21]^ The continuous decrease in the incidence of SQC and SMC is thought to be due to the decline in smoking prevalence.

Although the incidence rates of SQC and SMC decreased for both genders, the rates among females in the younger age group (35--64 years) levelled off ([eFigure 1](#sm04){ref-type="supplementary-material"} and [eFigure 3](#sm06){ref-type="supplementary-material"}). Smoking prevalence among females in their 20s and 30s increased from 1965 and almost levelled off at about 17--23% in 1990--2008.^[@r21]^ It was reported that the prevalence of ever smoking by birth cohort among Japanese females continuously increased from the 1930s birth cohort and exceeded 20% by the 1973 birth cohort. Moreover, it was also reported that the mean age of smoking initiation among females declined noticeably during this period.^[@r22]^ The high smoking prevalence among females who were born after the 1960s is possibly related to the stable trends of SQC and SMC among females in the younger age group (35--64 years). The above findings suggest that it is necessary to monitor the incidence rates of SQC and SMC and to reduce smoking prevalence, especially in younger females.

Smoking prevalence for males in Osaka is almost the same as for Japan as a whole (Osaka: 48.1% in 2001 and 33.6% in 2010; Japan as a whole: 48.4% in 2001 and 33.1% in 2010), while it is a little higher among females in Osaka (Osaka: 15.7% in 2001 and 12.3% in 2010; Japan as a whole: 14.0% in 2001 and 10.4% in 2010).^[@r23]^ It is possible that the impact of smoking on lung cancer incidence is greater for females in Osaka.

Trends in the incidence rates of ADC
------------------------------------

The incidence rate of ADC showed an increasing trend among all the age groups for both genders except for males in the 65--74 years age group ([eFigure 2](#sm05){ref-type="supplementary-material"}). An increase in incidence of ADC has been reported worldwide, especially for females in developed countries. However, the determining factor for the increase in ADC remains unclear.^[@r24]^ It has been suggested the switching from non-filtered cigarettes to filtered cigarettes in the 1960s is related to the increase in ADC and decrease in SQC and SMC.^[@r25]^ However, smoking prevalence has decreased since the 1960s, except among younger females, and cigarette consumption per capita has levelled off and then decreased since the late 1970s ([eFigure 4](#sm07){ref-type="supplementary-material"}).^[@r21],[@r26]^ Therefore, it is difficult to explain the increase in ADC incidence by smoking trends alone. One study has estimated the latency period between exposures to filter cigarettes and ADC development to be about 25 years,^[@r25]^ while another study suggested that it could be more than 30 years if cigarette consumption played a major role in development of ADC.^[@r27]^ If the latency period was about 30 years, the incidence rate of ADC in Osaka would be expected to have begun to level off or decrease from the 2000s.

On the other hand, ADC is the most common type of lung cancer in lifelong non-smokers.^[@r28],[@r29]^ Specific gene mutations, such as EGFR mutations, might be related to the relationship between ADC and never smokers. It has been reported that EGFR mutations are more frequent in females, patients with ADC, never smokers, and people of East Asian ethnicity.^[@r30]^ The higher percentage of never smokers among females than males is probably one reason why the incidence of ADC increased more steeply for females than males. Passive smoking is also considered to be a risk factor for lung cancer,^[@r31]^ and an association has been clearly identified for ADC incidence (HR 2.03; 95% CI, 1.07--3.86).^[@r32]^ It is necessary to monitor trends in ADC and investigate the association between smoking and ADC incidence, with consideration of various factors, such as different distributions of EGFR mutations between ethnicities, smoking patterns, and genders.

Another possible risk factor for lung cancer is air pollution.^[@r33]^ Long-term exposure to NOx has been reported as a possible cause for a temporal increase in ADC incidence in the United States.^[@r34]^ According to a survey by the Japanese government, annual average concentrations of SO~2~ and SPM have decreased since the 1970s, while NO~2~ concentration has levelled off and slightly decreased from the 2000s ([eFigure 4](#sm07){ref-type="supplementary-material"}).^[@r35]^ Therefore, air pollution is not likely to be a major reason for the increased incidence rates of ADC.

Comparison with the results of other studies
--------------------------------------------

Our study confirmed the increase in incidence of ADC and the decrease in incidence of SQC and SMC in Osaka, which has already been shown by a previous study.^[@r06]^ According to a study of nine population-based prefectural cancer registries in Japan,^[@r25]^ incidence rates of SQC have recently decreased for both genders, which is consistent with our results in Osaka. However, the incidence of ADC in males has levelled off (APC 0.2%; 95% CI, −1.6% to 1.9%) since 1998, which is different from the results in Osaka. It seems that there are some differences in trends for lung cancer incidence between Osaka and other prefectures, especially for ADC.

According to lung cancer trends by histological type in other countries,^[@r36]^ incidence rates of SQC and SMC decreased for males and incidence of ADC increased for females in North America, Australia, and several European countries. Nevertheless, there were some differences. In North America, Australia, Denmark, and Iceland, incidence rates of ADC for males and lung cancer for all histological types for females levelled off, while in the other European countries, as in Osaka, incidence of ADC in males and lung cancer of all histological types in females increased. This is probably because smoking prevalence for both genders in North America, Australia, Denmark, and Iceland was lower and declined more sharply between 1980 and 2012 than in other countries, including Japan.^[@r37],[@r38]^ Regarding trends in Hong Kong and Tianjin, China,^[@r39],[@r40]^ incidence rates of lung cancer significantly decreased for both genders after the 1980s and 1990s, respectively. In these two regions, ADC incidence levelled off or decreased and SQC incidence has decreased recently for both genders. However, male smoking prevalence in China among adults aged 15 or above was high and has decreased slowly (61% in 1984 and 52.9% in 2010).^[@r41],[@r42]^ Although smoking is closely associated with lung cancer incidence, it appears that we cannot fully understand trends in lung cancer by trends in smoking prevalence alone. Interpreting these trends more accurately requires that we also study the influence of the spread of cancer screening or exposure to other risk factors on lung cancer incidence.

Limitations
-----------

There are several limitations to the present study. The OCR included cases with unspecified histological diagnosis. Although the percentage of cases without histological diagnosis decreased over the years, about one-third of the cases had an unspecified histological diagnosis in 2005--2008 (Table [1](#tbl01){ref-type="table"}). We used the MI approach to solve this problem. However, when we use the MI approach, the mechanism of missingness should be missing at random, where the chance of data being missing is independent of unseen values.^[@r10],[@r43]^ Although we assumed that this was the case for the data from OCR, it is difficult to test whether or not this assumption is valid.

The quality of cancer registry data is usually determined using the proportion of death certificate only (DCO) cases and microscopic verified (MV) cases (DCO% and MV%).^[@r08]^ For the OCR, DCO% and MV% of all cancers are as follows^[@r44]^: DCO% in 1987, 1997, and 2007 were 24%, 15%, and 11.6% for males and 21.1%, 14%, and 11.8% for females, respectively; MV% in 1992, 1997, and 2007 were 70%, 70%, and 77.6% for males and 73%, 72%, and 75.8% for females, respectively. DCO% of the OCR has improved over these periods, which might have influenced trends in incidence rates of lung cancer. It was difficult to evaluate the influence of these factors in our analysis.

Conclusion
----------

In this study, we investigated trends in incidence and mortality rates of lung cancer and incidence rates by histological type and age group. The incidence rates of SQC and SMC decreased with the decline in smoking prevalence, which probably led to the change in trends in lung cancer incidence rates from the mid-1980s. It was difficult to explain why the incidence rates of ADC continued to increase for both males and females. Therefore, subsequent studies should carefully monitor trends in lung cancer incidence by histological type, especially trends for ADC. The relationship between the incidence of ADC and its possible risk factors also warrants clarification.

ONLINE ONLY MATERIALS
=====================

###### Trends in truncated age-standardized incidence rates for squamous cell carcinoma with joinpoint analysis.

###### Trends in truncated age-standardized incidence rates for adenocarcinoma with joinpoint analysis.

###### Trends in truncated age-standardized incidence rates for small cell carcinoma with joinpoint analysis.

###### Trends in truncated age-standardized incidence rates of squamous cell carcinoma in Osaka, Japan from 1975 to 2008.

###### Trends in truncated age-standardized incidence rates of adenocarcinoma in Osaka, Japan from 1975 to 2008.

###### Trends in truncated age-standardized incidence rates of small cell carcinoma in Osaka, Japan from 1975 to 2008.

###### Trends in age-standardized incidence rates of lung cancer by histological type in Osaka from 1975 to 2008, with trends in smoking prevalence and average concentration of SO~2~, NO~2~, and SPM.
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